by Walter Gunzburg | Jun 26, 2023 | News
FIGURE 6. Secretion of IgG from encapsulated clone 6B1 cells. (A). Representative image of capsule four in bright field and fluorescence showing homogenous eGFP expression in encapsulated cells. Encapsulation of clone 6B1 cells. Cells were encapsulated in...
by Walter Gunzburg | Jun 20, 2023 | News
Cell-in-a-Box can be used to protect fragile cells from sheer stress occurring in bioreactors. Products produced by the cells can be easily harvested from the bioreactor since Cell-in-a-Box is a porous structure. Encapsulated cells can also be released from...
by Walter Gunzburg | May 18, 2023 | News, Press Release
This press release can be viewed online at: https://www.einpresswire.com/article/634030792/ The joint treatment will be developed for multiple myeloma, a type of blood cancer that affects plasma cells. SINGAPORE, SINGAPORE, May 18, 2023/EINPresswire.com/ — The...
by Walter Gunzburg | Apr 1, 2023 | News, Press Release
This press release can be viewed online at: https://www.einnews.com/pr_news/625357967 SINGAPORE, SINGAPORE, March 31, 2023 /EINPresswire.com/– SGAustria (“Austrianova”), a leading provider of cell biological products and services, today announced details about...
by Walter Gunzburg | Mar 2, 2023 | News, Press Release
This press release can be viewed online at: https://www.einpresswire.com/article/619655265 Checkmate Capital makes preferred equity investment in Austrianova parent company SGAustria for GMP facility expansion SINGAPORE, March 1, 2023 /EINPresswire.com/ — SG...
by Walter Gunzburg | Feb 3, 2023 | News
We have shown the incredible physical robustness of Cell-in-a-Box® capsules placed under compression forces using a piston (see video) and also the stability of capsules when they are injected through a needle. Cell-in-a-Box® capsules are also stable for many...
by Walter Gunzburg | Dec 21, 2022 | News
Austrianova/SGAustria is pleased to announce that during the last year it has made major progress and achieved some significant milestones. During 2022, as well as our ongoing projects, the Company has acquired three new partners all involved in cutting edge therapy...
by Walter Gunzburg | Nov 29, 2022 | News
‘ ”’ ‘ All therapeutics go through three phasese of clinical trial testing (phase 1, 2 and 3) before market authorization is possible and they are approved for use in patients. Because late stage clinical trials involve more subjects than early...
by Walter Gunzburg | Sep 16, 2022 | News
Austrianova Chief Production Officer speaking at Bio Asia Pacific 2022 about Austrianova’s GMP Cell Encapsulation and Cell Banking...
by Walter Gunzburg | Jun 30, 2022 | News
WARNING: it has come to our attention that persons unknown are impersonating Austrianova through job interviews and job offers via Austrianova.co (not our official address which is Austrianova.com). We are currently not hiring and we do NOT conduct any...
